Fig. 4: The monocyte signature, a low TREM2 expression and a high SMARCD3 expression are associated with survival irrespective of treatment arm and are thus prognostic factors. | Nature Communications

Fig. 4: The monocyte signature, a low TREM2 expression and a high SMARCD3 expression are associated with survival irrespective of treatment arm and are thus prognostic factors.

From: Immunomic longitudinal profiling of the NeoPembrOv trial identifies drivers of immunoresistance in high-grade ovarian carcinoma

Fig. 4

A, C, D PFS (left) and OS (right) curves of patients included in the NeoPembrOv trial (without distinction of treatment arm) according to the expression of a monocyte gene signature (High (red), n = 10; Low (blue), n = 43) (A), TREM2 gene expression (High (red), n = 16; Low (blue), n = 37) (C) and SMARCD3 gene expression (High (red), n = 35; Low (blue), n = 18) (D). Patients were stratified based on a positive (=high) versus negative (=low) expression score (A), and on the best cut-off (B, C). Statistical comparison of survival curves was performed using the likelihood ratio test. B Spearman correlation between monocyte and type 2 macrophage expression signature. Error bands represents the 95% CI as a shaded gray area. Source data are provided as a Source Data file.

Back to article page